Divestiture

The Alaska Native corporation's spring distribution highlights a unique model where financial success directly fuels cultural vitality and environmental restoration.

Stepping into the role of Chairman and CEO, Dianne Taube ushers in a new era for the influential foundation with a focus on innovation and measurable impact.

A major US mutual life insurer is launching a Bermuda reinsurer with Agam Capital's help, highlighting a trend of using tech to optimize capital offshore.

GoldenTree's oversubscribed $3B fund close highlights a major shift as institutional investors seek flexible, high-yield private credit strategies.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

Italian infrastructure giant Mundys can now own nearly 30% of Getlink, a key move in European transport that passed the UK's strict security review.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

The diagnostics firm posts strong 2025 growth, but the impending loss of a key partner puts its high-stakes strategic pivot squarely to the test.

A new IP firm, led by an industry veteran, acquired 500+ Avaya networking patents. The move signals a new era for tech licensing and innovation.

Lupin has launched a generic version of the blockbuster diabetes drug Farxiga, signaling lower costs for patients and a major shake-up in the SGLT2 market.

A court ruling dismisses a lawsuit against Montclair's Lackawanna Plaza plan, clearing the path for the long-stalled, transformative project to proceed.

An investigation into a Florida 'trash school' reveals a national crisis of toxic dumps near schools, disproportionately harming children of color.

As drug-resistant superbugs threaten modern medicine, a novel liquid therapeutic from Seres Therapeutics offers a lifeline for the most vulnerable patients.

Beasley Broadcast Group reports a staggering $190M Q4 loss after a massive asset write-down, but a major debt cut and digital growth signal a fight for survival.

Facing a shareholder revolt after a damning indictment, Supermicro launches a major probe into a $2.5B shadow trade scheme. Is it too little, too late?

With its Q1 earnings call on May 7, STARZ faces investor scrutiny on subscriber growth, content strategy, and its path to profitability post-spinoff.

A government shutdown threatens the annual memorial for fallen firefighters, leaving 204 families in limbo and a sacred promise hanging in the balance.

Lupin wins FDA approval for its generic dapagliflozin, a move set to slash costs for a blockbuster diabetes and heart drug and reshape patient care.

As Democrats demand Trump’s removal, Ralph Nader and Bruce Fein gather top legal minds to define the constitutional grounds for impeachment.